TOVX Stock Overview
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Theriva Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.45 |
| 52 Week High | US$1.20 |
| 52 Week Low | US$0.20 |
| Beta | 1.47 |
| 1 Month Change | 1.59% |
| 3 Month Change | 8.00% |
| 1 Year Change | -36.90% |
| 3 Year Change | -91.91% |
| 5 Year Change | -92.77% |
| Change since IPO | -99.92% |
Recent News & Updates
Shareholder Returns
| TOVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.8% | -4.7% | -3.7% |
| 1Y | -36.9% | -2.7% | 20.2% |
Return vs Industry: TOVX underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: TOVX underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| TOVX volatility | |
|---|---|
| TOVX Average Weekly Movement | 15.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TOVX's share price has been volatile over the past 3 months.
Volatility Over Time: TOVX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 22 | Steve Shallcross | therivabio.com |
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma.
Theriva Biologics, Inc. Fundamentals Summary
| TOVX fundamental statistics | |
|---|---|
| Market cap | US$7.68m |
| Earnings (TTM) | -US$18.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs TOVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TOVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.35m |
| Earnings | -US$18.35m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.6% |
How did TOVX perform over the long term?
See historical performance and comparison